Xencor Inc (NASDAQ:XNCR) — Market Cap & Net Worth
Market Cap & Net Worth: Xencor Inc (XNCR)
Xencor Inc (NASDAQ:XNCR) has a market capitalization of $827.65 Million ($827.65 Million) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9940 globally and #2653 in its home market, demonstrating a 6.92% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Xencor Inc's stock price $12.20 by its total outstanding shares 71410469 (71.41 Million). Review Xencor Inc total liabilities to assess the company's total debt and financial obligations.
Xencor Inc Market Cap History: 2015 to 2026
Xencor Inc's market capitalization history from 2015 to 2026. Data shows growth from $1.04 Billion to $871.21 Million (0.01% CAGR).
Index Memberships
Xencor Inc is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.03% | #275 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.00% | #1026 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.05% | #159 of 263 |
|
S&P Small-Cap 600 Index
SML
|
$1.65 Trillion | 0.05% | #503 of 602 |
Weight: Xencor Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Xencor Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Xencor Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
14.85x
Xencor Inc's market cap is 14.85 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.04 Billion | $27.76 Million | -$17.59 Million | 37.61x | N/A |
| 2016 | $1.88 Billion | $87.52 Million | $23.62 Million | 21.48x | 79.56x |
| 2017 | $1.57 Billion | $35.71 Million | -$48.92 Million | 43.83x | N/A |
| 2018 | $2.58 Billion | $40.60 Million | -$70.41 Million | 63.60x | N/A |
| 2019 | $2.46 Billion | $156.70 Million | $26.88 Million | 15.67x | 91.38x |
| 2020 | $3.12 Billion | $122.69 Million | -$63.54 Million | 25.39x | N/A |
| 2021 | $2.86 Billion | $275.11 Million | $82.63 Million | 10.41x | 34.67x |
| 2022 | $1.86 Billion | $164.58 Million | -$55.18 Million | 11.30x | N/A |
| 2023 | $1.52 Billion | $168.34 Million | -$126.09 Million | 9.01x | N/A |
| 2024 | $1.64 Billion | $110.49 Million | -$232.62 Million | 14.85x | N/A |
Competitor Companies of XNCR by Market Capitalization
Companies near Xencor Inc in the global market cap rankings as of June 17, 2026.
Key companies related to Xencor Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
Xencor Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Xencor Inc's market cap moved from $1.04 Billion to $ 871.21 Million, with a yearly change of 0.01%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $871.21 Million | -20.31% |
| 2025 | $1.09 Billion | -33.38% |
| 2024 | $1.64 Billion | +8.24% |
| 2023 | $1.52 Billion | -18.47% |
| 2022 | $1.86 Billion | -35.09% |
| 2021 | $2.86 Billion | -8.04% |
| 2020 | $3.12 Billion | +26.87% |
| 2019 | $2.46 Billion | -4.89% |
| 2018 | $2.58 Billion | +64.96% |
| 2017 | $1.57 Billion | -16.72% |
| 2016 | $1.88 Billion | +80.03% |
| 2015 | $1.04 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Xencor Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $827.65 Million USD |
| MoneyControl | $827.65 Million USD |
| MarketWatch | $827.65 Million USD |
| marketcap.company | $827.65 Million USD |
| Reuters | $827.65 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Xencor Inc
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for t… Read more